3’,5’-二-O-乙酰基O6-苄基-2’-脱氧鸟苷 | 144640-75-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 3’,5’-二-O-乙酰基O6-苄基-2’-脱氧鸟苷
• 中文别名: 3′，5′-二-O-乙酰基O6-苄基-2′-脱氧鸟苷
• 英文名称: 3',5'-di-O-acetyl-O⁶-benzyl-2'-deoxyguanosine
• 英文别名: 3',5'-di-O-acetyl-O6-benzyl-2'-deoxyguanosine；3',5'-Di-O-acetyl O6-Benzyl-2'-deoxyguanosine；[(2R,3S,5R)-3-acetyloxy-5-(2-amino-6-phenylmethoxypurin-9-yl)oxolan-2-yl]methyl acetate
• CAS: 144640-75-5
• 化学式: C₂₁H₂₃N₅O₆
• 分子量: 441.444
• InChiKey: QLUZVLZNJMLEJA-GVDBMIGSSA-N

物化性质

• 沸点：
  678.7±65.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于二氯甲烷、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  3’,5’-二-O-乙酰基O6-苄基-2’-脱氧鸟苷 在 palladium diacetate 、 palladium on activated charcoal 三甲基氯硅烷 、 亚硝酸特丁酯 、 氢气 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 3.0h， 生成 Acetic acid (2R,3S,5R)-2-acetoxymethyl-5-{2-[3,4-bis-(tert-butyl-dimethyl-silanyloxy)-naphthalen-1-ylamino]-6-oxo-1,6-dihydro-purin-9-yl}-tetrahydro-furan-3-yl ester
  参考文献：
  名称：

  致癌多环芳烃与2'-脱氧核糖核苷的邻醌代谢产物的加合物的合成。

  摘要：

  [结构：见正文]报告了在致癌多环芳烃（BPQ和BAQ）的邻醌代谢产物在DNA中2'-脱氧腺苷和2'-脱氧鸟苷位点反应中形成的加合物的首次合成。这些合成需要邻苯二酚的受保护胺衍生物与2'-脱氧核糖核苷的适当保护的卤代嘌呤类似物的Pd催化偶联。

  DOI：

  10.1021/ol0475358
• 作为产物：
  描述：

  2'-脱氧鸟苷 在 吡啶 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 1,4-二氧六环 为溶剂， 反应 74.0h， 生成 3’,5’-二-O-乙酰基O6-苄基-2’-脱氧鸟苷
  参考文献：
  名称：

  β-Glucuronidase-Cleavable Prodrugs of O⁶-Benzylguanine and O⁶-Benzyl-2‘-deoxyguanosine

  摘要：

  Glucuronic acid linked prodrugs of O-6-benzylguanine and O-6-benzyl-2'-deoxyguanosine were synthesized. The prodrugs were found to be quite stable at physiological pH and were more than 200-fold less active as inactivators of O-6-alkylguanine-DNA alkyltransferase (alkyltransferase) than either O-6-benzylguanine or O-6-benzyl-2'-deoxyguanosine. beta-Glucuronidase from both Escherichia coli and bovine liver cleaved the prodrugs efficiently to release O-6-benzylguanine and O-6-benzyl-2'-deoxyguanosine, respectively. In combination with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), the prodrugs were not effective adjuvants for HT29 cell killing. However, as expected, incubation of these prodrugs with beta-glucuronidase in the culture medium led to much more efficient cell killing by BCNU as a result of the liberation of the more potent inactivators, O-6-benzylguanine and O-6-benzyl-2'-deoxyguanosine. These prodrugs may be useful for prodrug monotherapy of necrotic tumors that liberate beta-glucuronidase or for antibody-directed enzyme prodrug therapy with antibodies that can deliver beta-glucuronidase to target tumor cells.

  DOI：

  10.1021/jm0493865

文献信息

• [EN] BETA-GLUGURONIDASE CLEAVABLE PRODRUGS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS<br/>[FR] PROMEDICAMENTS A BASE D'AGENTS D'INACTIVATION DE L'O6-ALKYLGUANINE-ADN ALKYLTRANSFERASE, CLIVABLES PAR LA BETA-GLUCURONIDASE
  申请人：US GOV HEALTH & HUMAN SERV

  公开号：WO2006029065A1

  公开（公告）日：2006-03-16

  Disclosed are prodrugs of inactivators of 06-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the (3-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring­ substituted with one or more electron withdrawing groups; and C is an inactivator of AGT, e.g., a substituted or unsubstituted 06-benzylguanine or 06-benzyl-2'-deoxyguanosine. Also disclosed are pharmaceutical compositions comprising a prodrug and a pharmaceutically acceptable carrier, and a method of use of the prodrugs in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the 06-position of guanine.

  本发明公开了06-烷基鸟嘌呤-DNA烷基转移酶（AGT）失活剂的前药。这些前药可以被（3-葡萄糖醛酸酶酶）水解，该酶可以被注射到患者体内或由坏死肿瘤细胞产生。前药由公式A-B-C表示，其中A是通过其1-氧原子与B的苯环连接的葡萄糖醛酸残基；B是苄氧羰基基团，可以选择性地被一个或多个电子提取基团取代；而C是AGT的失活剂，例如取代或未取代的06-苄基鸟嘌呤或06-苄基-2'-脱氧鸟苷。本发明还公开了包含前药和药学上可接受的载体的制药组合物，以及在增强哺乳动物（例如人类）中肿瘤细胞的化疗治疗中使用前药的方法，该方法使用一种抗肿瘤烷基化剂，在鸟嘌呤的06位引起细胞毒性损伤。
• O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE INACTIVATORS AND BETA-GLUCURONIDASE CLEAVABLE PRODRUGS
  申请人：MOSCHEL C. Robert

  公开号：US20070213279A1

  公开（公告）日：2007-09-13

  Disclosed are prodrugs of inactivators of O 6 -alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring-substituted with one or more electron withdrawing groups; and C is an inactivator of AGT, e.g., a substituted or unsubstituted O 6 -benzylguanine or O 6 -benzyl-2′-deoxyguanosine, Also disclosed are additional inactivators of AGT, pharmaceutical compositions comprising an inactivator or prodrug and a pharmaceutically acceptable carrier, and a method of use of the inactivator or prodrug in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the O 6 -position of guanine.

  本发明公开了O6-烷基鸟嘌呤-DNA烷基转移酶（AGT）不活化剂的前药。这些前药可被β-葡萄糖醛酸酶酶水解，该酶可由患者口服或由坏死的肿瘤细胞产生。该前药的化学式为A-B-C，其中A是葡萄糖醛酸残基，通过其1-氧原子与B的苯环连接；B是苄氧羰基基团，可选地带有一个或多个电子吸引基；C是AGT的不活化剂，例如取代或未取代的O6-苄基鸟嘌呤或O6-苄基-2'-脱氧鸟苷。本发明还公开了其他AGT不活化剂、包含不活化剂或前药及其药学可接受载体的制药组合物，以及在使用抗肿瘤烷基化剂在哺乳动物（例如人类）中增强肿瘤细胞的化疗治疗中使用不活化剂或前药的方法。
• O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
  申请人：The United States of America as represented by the Department of Health and Human Services

  公开号：US07825096B2

  公开（公告）日：2010-11-02

  Disclosed are prodrugs of inactivators of O6-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the β-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrugs are represented by the formula A-B-C, wherein A is a glucuronosyl residue linked through its 1-oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring-substituted with one or more electron withdrawing groups; and C is an inactivator of AGT, e.g., a substituted or unsubstituted O6-benzylguanine or O6-benzyl-2′-deoxyguanosine. Also disclosed are additional inactivators of AGT, pharmaceutical compositions comprising an inactivator or prodrug and a pharmaceutically acceptable carrier, and a method of use of the inactivator or prodrug in enhancing the chemotherapeutic treatment of tumor cells in a mammal, e.g., a human, with an antineoplastic alkylating agent that causes cytotoxic lesions at the O6-position of guanine.

  本发明涉及一种O6-烷基鸟嘌呤-DNA烷基转移酶（AGT）不活化剂的前药。该前药可被β-葡萄糖醛酸酶酶水解，该酶可以被注射给患者或者由坏死的肿瘤细胞产生。该前药的化学式为A-B-C，其中A是通过其1-氧原子与B的苯环连接的葡萄糖醛酸残基；B是苄氧羰基基团，可以选择性地带有一个或多个电子提取基；而C是AGT的不活化剂，例如，取代或未取代的O6-苄基鸟嘌呤或O6-苄基-2'-脱氧鸟苷。本发明还涉及AGT的其他不活化剂，包括含有不活化剂或前药和药学上可接受的载体的制剂，以及使用不活化剂或前药增强哺乳动物（例如人类）的肿瘤细胞化疗治疗的方法，该化疗药物在鸟嘌呤的O6位引起细胞毒性损伤。
• Epoxide and diol epoxide adducts of polycyclic aromatic hydrocarbons at the exocyclic amino group of deoxyguanosine
  作者：Barbara Zajc、Mahesh K. Lakshman、Jane M. Sayer、Donald M. Jerina

  DOI：10.1016/s0040-4039(00)92649-2

  日期：1992.6

  Synthesis and separation of the diastereomeric trans N2-2'-deoxyguanosine adducts of tetrahydrophenanthrene 3,4-epoxide and benzo[a]pyrene 7,8-diol 9, 10-epoxide (benzylic hydroxyl group and epoxide oxygen trans), as well as the incorporation of the former into the pentanucleotide TpApG*pApT, are described.